CureVac, The Honest Company, Fisker & more


Take a look at some of the biggest movers in the premarket:

CureVac (CVAC) – CureVac shares plunged 46.2% in the premarket after the German drugmaker reported disappointing results from a study of its experimental Covid-19 vaccine. The treatment was 47% effective in a clinical trial, compared to more than 90% for other mRNA-based vaccines from Moderna (MRNA) and Pfizer (PFE).

Novavax (NVAX), BioNTech (BNTX) – On the heels of the CureVac news, Novavax added 3.4% in the premarket while BioNTech rose 2.6%. BioNTech’s Covid vaccine – developed in partnership with Pfizer – is already approved for use in the US, while Novavax reported 90% efficacy for its vaccine in a recent study.



0 0 votes
Article Rating

Jeep Grand Cherokee L arriving in showrooms to expand brand’s reach

Previous article

Business travel likely to resume in the fall, Hyatt Hotels CEO says

Next article

You may also like

Notify of
Inline Feedbacks
View all comments

More in Finance